Back to Search
Start Over
Arrowhead Pharmaceuticals Filed for Regulatory Clearance to Initiate Phase 1|2a Study of ARO-CFB for Complement Mediated Kidney Disease
- Source :
- Plus Company Updates. December 22, 2023
- Publication Year :
- 2023
-
Abstract
- PASADENA: Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, the company's investigational RNA interference [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.777372376